Table 3.
Structure and applications of different anti-galectin agents described in this review.
| Type | Name | N° | Structure | Tumor type tested | Reference | |
|---|---|---|---|---|---|---|
| Low-molecular weight inhibitors | Lactosylated steroid | 12 |  |
Mouse models of mouse lymphoma and human gliblastoma | (110) | |
| Allyl lactoside | 13 |  |
Human melanoma and small cell lung cancer cells | (111) | ||
| Thiodigalactoside (TDG) | 14 |  |
Murine lung metastasis | (112) | ||
| 3,3′-di-(3-metoxibenzamido)-thiodigalactoside | 15 |  |
(113) | |||
| 3,3′-ditriazolyl thiodigalactoside | 16 |  |
(113) | |||
| Td131_1 | 17 |  |
Papillary thyroid cancer | (114) | ||
| Talosamide | 18 |  |
(115) | |||
| Glycoamines | Lactulose-l-leucine (Lac-l-Leu) | 19 |  |
Human breast carcinoma, prostate cancer | (116–118) | |
| N-lactulose-octamethylenediamine (LDO) | 20 |  |
Melanoma and lung carcinoma | (119) | ||
| N, N′-dilactulose-octamethylenediamine (D-LDO) | 21 |  |
||||
| N, N′-dilactulose-dodecamethylenediamine (D-LDD) | 22 |  |
||||
| Polysaccharide-based compounds | Pectin-derived compounds | Pectasol-C | 23 |  |
Prostate and human breast cancer | (120–124) |
| GCS-100 | 24 | Myeloma and leukemia | (125, 126) | |||
| GR-MD-02 | 25 |  |
Melanoma | (127) | ||
| Galactomannan-derived compound | GM-CT-01 (DAVANAT) | 26 |  |
Colon cancer | (128) | |
| Peptides | G3-A9 | 27 | PQNSKIPGPTFLDPH | Breast carcinoma metastasis, prostate cancer | (129, 130) | |
| G3-C12 | 28 | ANTPCGPYTHDCPVKR | ||||
| Anginex | 29 |  |
Ovarian carcinoma | (131) | ||
| Peptidomimetics | 6DBF7 | 30 |  |
Ovarian carcinoma | (132) | |
| OTX008 | 31 |  |
Ovarian carcinoma and murine melanoma and glioblastoma | (133, 134) | ||